Intensive integrated therapy of type 2 diabetes: Implications for long-term prognosis

Diabetes

Volumn 53, Issue SUPPL. 3, 2004, Pages

  Gæde, Peter ^a   Pedersen, Oluf ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ISOPHANE INSULIN; PLACEBO; SULFONYLUREA DERIVATIVE;

AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG EFFECT; DRUG TARGETING; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; INTENSIVE INTEGRATED THERAPY; LIFESTYLE; MICROALBUMINURIA; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ALGORITHMS; BEHAVIOR THERAPY; DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; PROGNOSIS; TIME FACTORS;

EID: 9444245001     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.suppl_3.S39     Document Type: Conference Paper

References (55)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828, 1998
3. Standl E, Balletshofer B, Danl B, Weichenhain B, Stiegler H, Hormann A: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39:1540-1545, 1996
4. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
5. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 13:1865-1873, 1993
6. Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN: Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 132:605-611, 2000
7. The Heart Outcomes Prevention Evaluation Study: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
8. UKPDS Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study CUKPDS) Group. Lancet 352:837-853, 1998
9. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
10. Parving HH, Lehnert H, Bröchner-Mortensen J, Gonus R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
12. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H: Diabetes Intervention Study, multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14:308-317, 1991
13. Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA: Randomised controlled trial of structured personal care of type 2 diabetes mellitos. BMJ 323:970-975, 2001
14. Gæde P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353:617-622, 1999
15. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
16. Gæde P, Beck M, Vedel P, Pedersen O: Limited impact of lifestyle education in patients with type 2 diabetes mellitus and microalbuminuria: results from a randomized intervention study. Diabet Med 18:104-108, 2001
17. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
18. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897-1903, 2002
19. de Lorgeril M, Renaud S, Mamelle N: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343:1454-1459, 1994
20. Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K: Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:655-661, 1991
21. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998
22. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276:1886-1892, 1996
23. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350:757-764, 1997
24. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009, 1996
25. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
26. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
27. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
28. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes 20:614-620, 1997
29. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101:671-679, 2001
30. Hiss RG: Barriers to care in non-insulin-dependent diabetes mellitus: the Michigan experience. Ann Intern Med 124(1 Pt 2):146-148, 1996
31. Glasgow RE, McCaul KD, Schäfer LC: Barriers to regimen adherence among persons with insulin-dependent diabetes. J Behav Med 9:65-77, 1986
32. Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB: Work-site treatment of hypertension by specially trained nurses: a controlled trial. Lancet 2:1175-1178, 1979
33. Johansen J, Claudi T, Holtedahl K: Insulin treatment for poorly regulated diabetic patients in general practice: better regulation and symptom relief? Scand J Prim Health Care 17:244-249, 1999
34. Tashkin DP: Multiple dose regimens: impact on compliance. Chest 107 (Suppl. 5):176S-182S, 1995
35. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL: How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3273-3277, 1989
36. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881-1884, 1990
37. Hall D, Zeitler H, Rudolph W: Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 20:1549-1555, 1992
38. Teo KK, Yusuf S, Pfeffer M: Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360:1037-1043, 2002
39. Snoek FJ: Barriers to good glycaemic control: the patient's perspective. Int J Obes 24:S12-S20, 2000
40. The Danish Health Board: Type 2 diabetes: medical technology evaluation of screening, diagnostics and treatment. Medical Technology Evaluation Report 5 (1), 2003
41. Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UK-PDS 41). BMJ (Clin Res Ed) 320:1373-1378, 2000
42. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C: Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 44:298-304, 2001
43. UK Prospective Diabetes Study Group. Stearne MR, Palmer SL, Hammersley MS, Franklin SL, Spivey RS, Levy JC: Cost-effectiveness analysis of improved blood-pressure control in hypertensive patients with type-2 diabetes: UKPDS-40. BMJ (Clin Res Ed) 317:720-726, 1998
44. Jönsson B, Cook JR, Pedersen TR: The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 42:1293-1301, 1999
45. The CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
46. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
47. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
48. Diabetes Prevention Program Research Group: Reduction in the Incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
49. Rosenbaum M, Leibel RL, Hirsch J: Medical progress: obesity. N Engl J Med 337:396-407, 1997
50. UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
51. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 25:412-419, 1985
52. Kris-Etherton PM, Harris WS, Appel LJ: Omega-3 fatty acids and cardiovascular disease. Arteriosclr Thromb Vasc Biol 23:151-152, 2003
53. Audelin MC, Genest J Jr: Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 159:497-511, 2001
54. Maeda K, Tautamoto T, Wada A: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36:1587-1593, 2000
55. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. JAMA 291:565-575, 2004